5 completed, 3 enrolling by invitation, 2 not yet recruiting, 2 recruiting. 6 Phase 2, 2 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Enrolling by invitation 1, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 2 | Enrolling by invitation 1, Not yet recruiting 1 |
| Not applicable | 1 | Completed 1 |
Follow Mycobacterium Abscessus Infection: new trials by email Literature Review of Mycobacterium Abscessus Infection trials Research Report on Mycobacterium Abscessus Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Ceftriaxone for Injection, Amoxicillin - Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection | Phase 2 | Not yet recruiting | The University of Queensland | 300 | 2027-04-01 | 2026-03-20 |
| Bacteriophage for Chronic Multidrug-Resistant Mycobacterium Abscessus Subsp. Abscessus Pulmonary Infection DP-QB-MYA-002 - Mycobacterium Abscessus Infection, Bacteriophage Therapy | Phase 1 | Not yet recruiting | Alberta Health services | 1 | 2026-07-02 | 2026-02-24 |
| Epetraborole in Patients With Mycobacterium Abscessus Lung Disease Epetraborole, Placebo - Mycobacterium Abscessus Infection | Phase 2 | Recruiting | Kevin Winthrop | 84 | 2026-03-30 | 2026-05-06 |
| Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households Multi-modal NTM diagnostic including PCR, WGS, culture - Cystic Fibrosis (CF), Mucoviscidosis | Recruiting | Research Center Borstel | 120 | 2026-02-16 | 2026-08-19 | |
| Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection Mycobacteriophage Muddy_HRMN0052, Amikacin Injection, Clofazimine - Non-Tuberculous Mycobacterial (NTM) Pneumonia, Mycobacterium Abscessus Infection | Phase 1 | Enrolling by invitation | Vancouver Coastal Health | 1 | 2026-01-11 | 2026-06-03 |
| Clinical Study on the Early Bactericidal Activity of Contezolid Against Mycobacterium Abscessus Disease Contezolid, linezolid - Monotherapy, Mycobacterium Abscessus Infection | Phase 2 | Enrolling by invitation | Beijing Chest Hospital | 24 | 2026-01-01 | 2026-01-28 |
| Study to Evaluate the Efficacy of Delpazolid as Add-on Therapy in Refractory Mycobacterium Abscessus Complex Delpazolid - Nontuberculous Mycobacterium Infection, Mycobacterium Abscessus Infection | Phase 2 | Completed | LigaChem Biosciences, Inc. | 24 | 2024-01-16 | 2026-07-10 |
| Treatment Outcome Between Mycobacterium Abscessus Infection in Chronic Lung Disease and Acquired Interferon-gamma Autoantibody Syndrome Appropriate treatment - Mycobacterium Abscessus Infection, Adult-Onset Immunodeficiency With Acquired Anti-Interferon-Gamma Autoantibodies | Completed | King Chulalongkorn Memorial Hospital | 36 | 2022-06-15 | 2023-10-10 | |
| Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc) Omadacycline Oral Tablet, Placebo - Mycobacterium Infections, Nontuberculous, Mycobacterium Abscessus Infection | Phase 2 | Completed | Paratek Pharmaceuticals Inc | 66 | 2021-10-15 | 2025-07-30 |
| A Pilot Study to Assess the Effect of Intermittent iNO on the Treatment of NTM Lung Infection in CF and Non-CF Patients LungFit - Non-Tuberculous Mycobacterial Pneumonia, Cystic Fibrosis | Not applicable | Completed | Beyond Air Inc. | 15 | 2020-12-07 | 2022-12-16 |
| Inhaled Nitric Oxide for Patients With MABSC Nitric Oxide - Mycobacterium Abscessus Infection | Phase 2 | Completed | Beyond Air Inc. | 9 | 2017-07-24 | 2019-07-09 |
| To Evaluate the Clinical Efficacy and Safety of Omadacycline in the Treatment of Mycobacterium Abscessus Infection. Omadacycline Treatment Group - Mycobacterium Abscessus Infection, NTM Lung Infection Due to MAC | Enrolling by invitation | Beijing Chest Hospital | 200 | 2014-01-01 | 2026-05-29 |
Mycobacterium Infections, Nontuberculous (12) · Cystic Fibrosis (2) · Lung Diseases (2) · Infections (1) · Mycobacterium avium-intracellulare Infection (1) · Pneumonia (1)
Actinomycetales Infections (12) · Bacterial Infections (12) · Bacterial Infections and Mycoses (12) · Gram-Positive Bacterial Infections (12) · Mycobacterium Infections (12) · Infections (11) · Respiratory Tract Diseases (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Digestive System Diseases (2) · Genetic Diseases, Inborn (2) · Infant, Newborn, Diseases (2) · Lung Diseases (2) · Pancreatic Diseases (2) · Respiratory Tract Infections (1)
Linezolid (3) · Amikacin (2) · Cilastatin, Imipenem Drug Combination (2) · Clofazimine (2) · Trimethoprim, Sulfamethoxazole Drug Combination (2) · bedaquiline (2) · omadacycline (2) · Amoxicillin (1) · Cefoxitin (1) · Ceftaroline (1) · Ceftriaxone (1) · Clarithromycin (1) · Culture Techniques (1) · Doxycycline (1) · Ethambutol (1)
Beijing Chest Hospital (2) · Beyond Air Inc. (2) · Alberta Health services (1) · Kevin Winthrop (1) · King Chulalongkorn Memorial Hospital (1) · LigaChem Biosciences, Inc. (1) · Paratek Pharmaceuticals Inc (1) · Research Center Borstel (1) · The University of Queensland (1) · Vancouver Coastal Health (1)
China (2) · United States (2) · Australia (1) · Canada (1) · Germany (1) · Israel (1) · South Korea (1) · Thailand (1)
Alexander Mischnik, Prof. Dr. med. (1) · Amy Manley (1) · Chusana Suankratay, M.D., Ph.D. (1) · Kevin L Winthrop, MD, MPH (1) · Warat Usawakidwiree, M.D. (1) · Wenjuan Nie, Director (1)